Volume 8, Issue 1, Pages (July 2003)

Slides:



Advertisements
Similar presentations
Volume 17, Issue 4, Pages (April 2009)
Advertisements

Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector  Wei Huang, Travis McMurphy,
Volume 15, Issue 6, Pages (June 2007)
Volume 3, Issue 5, Pages (May 2001)
Molecular Therapy - Methods & Clinical Development
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver  Wei Huang, Xianglan Liu,
From: AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo
Volume 16, Issue 3, Pages (March 2008)
Volume 2, Issue 1, Pages (July 2000)
A MicroRNA124 Target Sequence Restores Astrocyte Specificity of gfaABC1D-Driven Transgene Expression in AAV-Mediated Gene Transfer  Grit Taschenberger,
Volume 25, Issue 3, Pages (March 2017)
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Molecular Therapy - Methods & Clinical Development
Ashley L Cooney, Brajesh K Singh, Patrick L Sinn  Molecular Therapy 
Volume 16, Issue 3, Pages (March 2008)
Volume 11, Issue 6, Pages (May 2015)
Volume 14, Issue 4, Pages (October 2006)
Neeltje A Kootstra, Ryusuke Matsumura, Inder M Verma  Molecular Therapy 
Volume 17, Issue 12, Pages (December 2009)
Volume 12, Issue 3, Pages (September 2005)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Molecular Therapy - Methods & Clinical Development
Volume 21, Issue 8, Pages (August 2013)
Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver  Wei Huang, Xianglan Liu,
Volume 2, Issue 1, Pages (July 2000)
Volume 22, Issue 10, Pages (October 2014)
Volume 9, Issue 4, Pages (April 2004)
Volume 15, Issue 2, Pages (February 2007)
Volume 9, Issue 6, Pages (June 2004)
High-accuracy biodistribution analysis of adeno-associated virus variants by double barcode sequencing  Damien Marsic, Héctor R Méndez-Gómez, Sergei Zolotukhin 
Noninvasive Optical Imaging of Firefly Luciferase Reporter Gene Expression in Skeletal Muscles of Living Mice  Joseph C. Wu, Gobalakrishnan Sundaresan,
Volume 5, Issue 2, Pages (February 2002)
Volume 15, Issue 1, Pages (January 2007)
Volume 3, Issue 4, Pages (April 2001)
Spatially and Temporally Regulated NRF2 Gene Therapy Using Mcp-1 Promoter in Retinal Ganglion Cell Injury  Kosuke Fujita, Koji M. Nishiguchi, Yukihiro.
J.P O'Rourke, H Hiraragi, K Urban, M Patel, J.C Olsen, B.A Bunnell 
Volume 16, Issue 6, Pages (June 2008)
Volume 19, Issue 2, Pages (February 2011)
piggyBac Transposon-mediated Long-term Gene Expression in Mice
Volume 12, Issue 5, Pages (November 2005)
Volume 10, Issue 4, Pages (October 2004)
Endothelial targeting of the Sleeping Beauty transposon within lung
Molecular Therapy - Nucleic Acids
Generation and molecular characterization of LV producer cell lines
Volume 10, Issue 4, Pages (October 2004)
Molecular Therapy - Methods & Clinical Development
Volume 11, Issue 6, Pages (June 2005)
Effect of Genome Size on AAV Vector Packaging
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 4, Issue 6, Pages (December 2001)
J.M.I. Malik, Z. Shevtsova, M. Bähr, S. Kügler  Molecular Therapy 
Changyu Zheng, Bruce J. Baum  Molecular Therapy 
Volume 6, Issue 3, Pages (September 2002)
Volume 3, Issue 6, Pages (June 2001)
piggyBac-mediated phenotypic correction of factor VIII deficiency
Abhijit De, Xiaoman Zhou Lewis, Sanjiv Sam Gambhir  Molecular Therapy 
Volume 15, Issue 5, Pages (May 2007)
Quan Jin, Chunping Qiao, Jianbin Li, Juan Li, Xiao Xiao 
Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma  Chien-Kuo.
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Molecular Therapy - Methods & Clinical Development
Volume 15, Issue 7, Pages (July 2007)
Volume 7, Issue 1, Pages (January 2003)
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
Volume 13, Issue 1, Pages (January 2006)
Volume 13, Issue 5, Pages (May 2006)
Volume 17, Issue 6, Pages (June 2009)
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Volume 14, Issue 1, Pages (July 2006)
Molecular Therapy - Methods & Clinical Development
Presentation transcript:

Volume 8, Issue 1, Pages 90-98 (July 2003) Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero  Gerald S Lipshutz, Deborah Titre, Mary Brindle, Angelina R Bisconte, Christopher H Contag, Karin M.L Gaensler  Molecular Therapy  Volume 8, Issue 1, Pages 90-98 (July 2003) DOI: 10.1016/S1525-0016(03)00132-1 Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 1 Schematic representations of viral vectors constructed. AAV2 and AAV5 vectors were constructed using either the cytomegalovirus (CMV) promoter or the elongation factor 1 alpha (EF1α) promoter. AAV2 and AAV5 EF1α-luc contained the bovine growth hormone polyadenylation signal (BGH An), while the other two vectors included the SV40 polyadenylation sequences (SV40 An). The woodchuck posttranscriptional regulatory element (WPRE) was inserted 3′ of the luciferase cassette in the AAV5 vector. ITR, inverted terminal repeats. Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 2 Expression in 293 human embryonic kidney cells. Cells were transduced in vitro with 1 × 1010 genomes of rAAV, and luciferase expression was analyzed by luminometry. The y axis indicates the relative light units (RLU) per 1 × 106 293 cells. The AAV vectors used, as well as the control, are designated above each bar. Error bars represent the standard error of the mean (SEM). Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 3 Graphic representation of longitudinal in vivo bioluminescence studies after AAV2 delivery. Mice were imaged repetitively over 18 months after in utero injection of rAAV2 containing either the CMV or the EF1α promoter. Total bioluminescence was quantified and plotted over time (indicated on the x axis). Data are plotted as counts per 5 min (indicated on the y axis). Each time point represents data from ≥4 animals. Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 4 Graphic representation of longitudinal in vivo bioluminescence studies after AAV5 delivery. Mice were serially followed over 15 months after in utero injection of rAAV5 containing the CMV promoter. Total bioluminescence was quantified and plotted over time (indicated on the x axis). Data are plotted as counts per 1 s (indicated on the y axis). This imaging system is more sensitive than equipment used in Fig. 3, as the data were collected over 1 s. Each time point represents data from ≥4 animals. Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 5 Longitudinal in vivo bioluminescence imaging after delivery of AAV5 CMV-luc-WPRE. Serial images captured from 2 weeks after birth to 15 months of life in analysis of a mouse injected in utero with 3 × 1011 genomes of AAV5 CMV-luc-WPRE. Image analysis was performed with the same parameters at each time point. The age of the animal at each time point is indicated above the image. The reference pseudocolor scale is the same at all time points. Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 6 Graphic summary of in vivo bioluminescence imaging analysis of adult animals after in utero injection. Mice were transduced in utero with equal numbers of genomes of rAAV. Expression was quantified by bioluminescence imaging. The y axis indicates the counts per second in tissues transduced by each vector (n at each ≥5). The AAV vectors administered and the uninjected control are indicated above each bar. Error bars represent the SEM. Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions

FIG. 7 Analysis of tissue distribution of AAV2 and AAV5. (A) Graphic summary comparing the tissue expression of AAV2 and AAV5 CMV-promoter vectors after in utero intraperitoneal injection. The y axis indicates the relative light units (RLU)/μg protein, a measurement of the quantity of luciferase. On the x axis is the name of each tissue. (B) PCR summary of comparison of vector distribution of AAV5 CMV, (C) of AAV2 CMV, and (D) of negative control: β-actin was used as a control for genomic DNA loading. The gels are representative of all the mice examined. Molecular Therapy 2003 8, 90-98DOI: (10.1016/S1525-0016(03)00132-1) Copyright © 2003 The American Society of Gene Therapy Terms and Conditions